Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006376 · ClinicalTrials.gov registry record · Phase 2
R115777 in Treating Patients With Advanced Bladder Cancer
A Phase 2 study of Bladder Cancer and Transitional Cell Cancer of the Renal Pelvis and Ureter, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Study locations
NCT00006376: Completed Phase 2 study of Bladder Cancer and Transitional Cell Cancer of the Renal Pelvis and Ureter, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT00006376 is a Phase 2 study of Bladder Cancer and Transitional Cell Cancer of the Renal Pelvis and Ureter that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006376, a Phase 2 study of Bladder Cancer and Transitional Cell Cancer of the Renal Pelvis and Ureter, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have advanced bladder cancer.
Conditions Studied
Interventions
- DRUG chemotherapy
- DRUG tipifarnib
Study Locations (2)
California
- UCSF Cancer Center and Cancer Research Institute - San Francisco
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-03 |
| Est. Completion | 2005-05 |
| Phase | Phase 2 |
What the finished NCT00006376 record still lists
NCT00006376 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 2 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 2 interventions - of which chemotherapy is the first listed.
NCT00006376 reports a single indexed study location in California, Florida.
Frequently Asked Questions
What is clinical trial NCT00006376 about?
NCT00006376 is a clinical study titled "R115777 in Treating Patients With Advanced Bladder Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have advanced bladder cancer.
What is the current status of trial NCT00006376?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-03. Estimated completion is 2005-05.
What conditions does trial NCT00006376 study?
This clinical trial studies the following conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter.
What interventions are being tested in trial NCT00006376?
The interventions under investigation include: chemotherapy (DRUG), tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00006376?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006376 being conducted?
This trial has 2 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Telehealth Intervention for Ostomy Self-Management
RECRUITING · Phase 2
-
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
RECRUITING · Phase 2
-
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
RECRUITING · Phase 2
-
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
RECRUITING · Phase 2
-
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
RECRUITING · Phase 2
-
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia